Spotlight

FDA Approves Zykadia Thumb

FDA Approves Zykadia (LDK378) in ALK+ Non-Small Cell Lung Cancer

Born at the NIBR Genomics Institute for the Novartis Foundation and advanced in collaboration with other groups across NIBR and Novartis, LDK378 has been on the fast track for approval since it received FDA Breakthrough Therapy designation in March 2013.


      Our research

      Our Research - Parisa's Family

      A Personal Quest to Prevent Blindness